ConductScience.org, home

Paper4561966

Mechanism of the antitumour effect of interferon in mice.

Gresser I and 2 others. Nature, 1972. Cited by 266 papers, by iCite.

Cite this record

ConductScience Library. Mechanism of the antitumour effect of interferon in mice. Papers, record 4561966. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4561966

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanism of the antitumour effect of interferon in mice.
PubMed
Journal
Nature
PubMed
Year
1972
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
266
iCite
Relative citation ratio, by iCite
4.81
iCite
Revised in PubMed
2021-01-02
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gresser II
2Maury CC
3Brouty-Boyé DD

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
InterferonsMajor topic
Leukemia L1210Major topic
Animals
Cell Division
Mice
Mice, Inbred DBA
Neoplasm Transplantation

Source PubMed

Download CSV of topics

Cited by51

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 266 citations.

PMIDTitleJournalYearIn PapersSource
42098864Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling.Breast Cancer Res2026https://conductscience.org/library/papers/42098864PubMed
36090998The gamble between oncolytic virus therapy and IFN.Front Immunol2022https://conductscience.org/library/papers/36090998PubMed
35251003Role of Hypoxia in the Interferon Response.Front Immunol2022https://conductscience.org/library/papers/35251003PubMed
34571733The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.Biology (Basel)2021https://conductscience.org/library/papers/34571733PubMed
33922087Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes.Biomolecules2021https://conductscience.org/library/papers/33922087PubMed
33842331Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.Front Oncol2021https://conductscience.org/library/papers/33842331PubMed
33408718Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease.Front Immunol2020https://conductscience.org/library/papers/33408718PubMed
31900802Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer.Immunol Res2019https://conductscience.org/library/papers/31900802PubMed
31771762Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.Semin Immunol2019https://conductscience.org/library/papers/31771762PubMed
30528455Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production.EBioMedicine2019https://conductscience.org/library/papers/30528455PubMed
28798748Role of Type I and II Interferons in Colorectal Cancer and Melanoma.Front Immunol2017https://conductscience.org/library/papers/28798748PubMed
28638743Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.Oncoimmunology2017https://conductscience.org/library/papers/28638743PubMed
26911188Antitumour actions of interferons: implications for cancer therapy.Nat Rev Cancer2016https://conductscience.org/library/papers/26911188PubMed
24400008Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.Front Immunol2013https://conductscience.org/library/papers/24400008PubMed
19710501CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.Blood2009https://conductscience.org/library/papers/19710501PubMed
17522764Interferon-beta inhibits liver metastases from murine colon 26 carcinoma and its highly metastatic variant.Surg Today2007https://conductscience.org/library/papers/17522764PubMed
12622455A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.J Neurooncol2003https://conductscience.org/library/papers/12622455PubMed
11778967Apoptosis and cell growth inhibition as antitumor effector functions of interferons.Med Oncol2001https://conductscience.org/library/papers/11778967PubMed
11131987Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma.J Neurooncol2000https://conductscience.org/library/papers/11131987PubMed
8919284Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases.Surg Today1996https://conductscience.org/library/papers/8919284PubMed

See all 51 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4561966

GET https://conductscience.org/api/papers/v1/4561966/cited_by?page=2